Core Viewpoint - The strategic partnership between Link Health Biotechnology Group, Wenzhou Medical University National Engineering Research Center, and Wenzhou Ouhai District People's Government aims to enhance research and development in the fields of skin, ophthalmology, and metabolic-related diseases, accelerating the implementation of the company's strategic initiatives [1][2] Group 1 - The collaboration will leverage the strengths of each party in research, industry, and policy to conduct comprehensive cooperation from basic research to clinical translation and industrialization in the application of growth factor drugs in regenerative medicine [1][2] - The partnership will explore the synergistic mechanisms of epidermal growth factor (EGF) and fibroblast growth factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair, with the goal of developing new compound formulations and delivery systems for diseases such as non-alcoholic steatohepatitis (NASH) and asthma [1][2] - This collaboration is expected to fill treatment gaps in multiple niche indications and unlock clinical and commercial value in the vast chronic disease market [1] Group 2 - The Wenzhou Medical University National Engineering Research Center is a leading independent entity focused on basic research and new drug development in the field of growth factor drugs, under the leadership of Academician Li Xiaokun from the Chinese Academy of Engineering [2] - The partnership is anticipated to enhance the company's R&D efficiency and success rate in the biopharmaceutical innovation sector, shorten product development cycles, and strengthen competitiveness in the EGF/FGF niche market [2] - The board views this collaboration as a key initiative to deepen the "government-university-enterprise" synergy and integrate into a national-level innovation platform, significantly accelerating the R&D and translation of cutting-edge innovation pipelines [2]
联康生物科技集团(00690)与温医大国家工程研究中心及温州市瓯海区人民政府达成战略合作